Tumor Characteristics and D2 Lymph Node Involvement in Gastric Cancer: A Clinicopathological Analysis (2018-2023) :.

IF 0.7 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Galen Medical Journal Pub Date : 2025-10-31 eCollection Date: 2025-01-01 DOI:10.31661/gmj.v14i.3949
Vahid Zangouri, Omid Akbari Alateimouri, Hamid Zaferani Arani, AmirAli Ghahramani
{"title":"Tumor Characteristics and D2 Lymph Node Involvement in Gastric Cancer: A Clinicopathological Analysis (2018-2023) :.","authors":"Vahid Zangouri, Omid Akbari Alateimouri, Hamid Zaferani Arani, AmirAli Ghahramani","doi":"10.31661/gmj.v14i.3949","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastric adenocarcinoma is a leading cause of cancer-related mortality worldwide, with lymph node involvement, particularly at the level 2 lymph node dissection (D2), serving as a critical determinant of prognosis and surgical strategy. This study aimed to evaluate the association between primary tumor characteristics and D2 lymph node involvement and examine these factors' impact on overall survival (OS) and disease-free survival (DFS) in patients undergoing curative gastrectomy.</p><p><strong>Materials and methods: </strong>A retrospective cohort study was conducted on 233 patients with histologically confirmed gastric cancer who underwent curative-intent surgery at Namazi Hospital (Shiraz, Iran) between April 2018 and March 2023. Clinicopathological variables, including tumor size, location, grade, and histologic type, were assessed with D2 lymph node involvement. Survival outcomes were analyzed using Kaplan- Meier estimates and compared using the log-rank test. Multivariate logistic regression and Cox proportional hazards models were employed to identify independent nodal involvement and survival predictors.</p><p><strong>Results: </strong>D2 lymphadenectomy in 38.1% of patients indicated no significant associations between D2 involvement and tumor grade (P=0.443), size (P=0.215), or location (P=0.522). However, D2 lymph node metastasis was associated with a significantly descending mean of overall survival (25.43 ± 3.36 months) compared to patients without D2 involvement (43.06 ± 2.59 months; P0.001). Tumor stage and size were strong predictors of survival, with Stage 3C patients revealing a median overall survival of 13.45 months and tumors 3 cm being associated with superior outcomes (P=0.002).</p><p><strong>Conclusion: </strong>D2 lymph node involvement reflects progressive disease biology and is an assertive prognostic marker in gastric adenocarcinoma. While tumor grade, size, and location were not independently predictive of D2 metastasis, tumor stage and nodal status were strongly associated with survival. These results reinforce the use of extended lymphadenectomy in selected patients and underscore the requirement for individualized surgical planning based on total tumor profiling.</p>","PeriodicalId":44017,"journal":{"name":"Galen Medical Journal","volume":"14 ","pages":"e3949"},"PeriodicalIF":0.7000,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12877330/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Galen Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31661/gmj.v14i.3949","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Gastric adenocarcinoma is a leading cause of cancer-related mortality worldwide, with lymph node involvement, particularly at the level 2 lymph node dissection (D2), serving as a critical determinant of prognosis and surgical strategy. This study aimed to evaluate the association between primary tumor characteristics and D2 lymph node involvement and examine these factors' impact on overall survival (OS) and disease-free survival (DFS) in patients undergoing curative gastrectomy.

Materials and methods: A retrospective cohort study was conducted on 233 patients with histologically confirmed gastric cancer who underwent curative-intent surgery at Namazi Hospital (Shiraz, Iran) between April 2018 and March 2023. Clinicopathological variables, including tumor size, location, grade, and histologic type, were assessed with D2 lymph node involvement. Survival outcomes were analyzed using Kaplan- Meier estimates and compared using the log-rank test. Multivariate logistic regression and Cox proportional hazards models were employed to identify independent nodal involvement and survival predictors.

Results: D2 lymphadenectomy in 38.1% of patients indicated no significant associations between D2 involvement and tumor grade (P=0.443), size (P=0.215), or location (P=0.522). However, D2 lymph node metastasis was associated with a significantly descending mean of overall survival (25.43 ± 3.36 months) compared to patients without D2 involvement (43.06 ± 2.59 months; P0.001). Tumor stage and size were strong predictors of survival, with Stage 3C patients revealing a median overall survival of 13.45 months and tumors 3 cm being associated with superior outcomes (P=0.002).

Conclusion: D2 lymph node involvement reflects progressive disease biology and is an assertive prognostic marker in gastric adenocarcinoma. While tumor grade, size, and location were not independently predictive of D2 metastasis, tumor stage and nodal status were strongly associated with survival. These results reinforce the use of extended lymphadenectomy in selected patients and underscore the requirement for individualized surgical planning based on total tumor profiling.

胃癌肿瘤特征与D2淋巴结累及的临床病理分析(2018-2023);
背景:胃腺癌是世界范围内癌症相关死亡的主要原因,其淋巴结累及,特别是2级淋巴结清扫(D2),是预后和手术策略的关键决定因素。本研究旨在评估原发性肿瘤特征与D2淋巴结受累之间的关系,并研究这些因素对根治性胃切除术患者总生存期(OS)和无病生存期(DFS)的影响。材料和方法:对2018年4月至2023年3月在Namazi医院(设拉子,伊朗)接受治疗目的手术的233例组织学证实的胃癌患者进行回顾性队列研究。临床病理变量,包括肿瘤大小、位置、分级和组织学类型,评估D2淋巴结受累情况。使用Kaplan- Meier估计分析生存结果,并使用log-rank检验进行比较。采用多变量logistic回归和Cox比例风险模型来确定独立的淋巴结累及和生存预测因子。结果:38.1%的D2淋巴结切除术患者D2受损伤与肿瘤分级(P=0.443)、大小(P=0.215)或位置(P=0.522)无显著相关性。然而,D2淋巴结转移与D2未受累患者(43.06±2.59个月;P0.001)相比,D2淋巴结转移与平均总生存期(25.43±3.36个月)显著下降相关。肿瘤分期和大小是生存的有力预测因素,3C期患者的中位总生存期为13.45个月,肿瘤3cm与较好的预后相关(P=0.002)。结论:D2淋巴结受累反映了疾病的进展生物学,是胃腺癌的一个可靠的预后标志物。虽然肿瘤分级、大小和位置不能独立预测D2转移,但肿瘤分期和淋巴结状态与生存密切相关。这些结果加强了扩大淋巴结切除术在选定患者中的应用,并强调了基于总体肿瘤谱的个体化手术计划的需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Galen Medical Journal
Galen Medical Journal MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
0.00%
发文量
13
期刊介绍: GMJ is open access, peer-reviewed journal in English and supported by Noncommunicable Diseases (NCD) Research Center of Fasa University of Medical Sciences that publishing by Salvia Medical Sciences Ltd. GMJ will consider all types of the following scientific papers for publication: - Editorial’s choice - Original Researches - Review articles - Case reports - Case series - Letter (to editors, to authors, etc) - Short communications - Medical Idea
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书